Overview

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period.
Phase:
Phase 2
Details
Lead Sponsor:
Conatus Pharmaceuticals Inc.
Collaborator:
Idun Pharmaceuticals
Treatments:
Caspase Inhibitors